相关实验视频
Updated: May 23, 2025

Inducible and Reversible Dominant-negative DN Protein Inhibition
Published on: January 7, 2019
通过向EZH2在三阴性乳腺癌中增加RB1表达
Renfei Yang1, Liyan Fei1,2, Yingfei Xue1,3
1Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
在三阴性乳腺癌 (TNBC) 中,RB1功能丧失与药物耐药性有关. 抑制EZH2表观遗传调节器可以促进RB1的表达,为TNBC提供一种新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 失去RB1功能是三阴性乳腺癌 (TNBC) 的标志.
- RB1功能障碍与TNBC中的治疗耐药性有关.
- 在TNBC中RB1的表观遗传调节仍然不完全理解.
研究的目的:
- 研究控制TNBC中RB1表达的表观遗传机制.
- 在TNBC的背景下,确定RB1的关键监管机构.
- 探索针对TNBC治疗的表观遗传通路的治疗策略.
主要方法:
- 生物信息学分析以确定RB1.1的上游监管机构.
- 实验验证包括EZH2抑制和RB1表达分析.
- 染色体免疫沉 (ChIP-qPCR) 和ATAC测序以评估基因素修饰和增强剂活性.
主要成果:
- Lysine histone methyltransferase EZH2 被确定为 RB1.1 的一个关键的上游调节器.
- 作为PRC2复合体的一部分,EZH2在RB1位点中介于H3K27的三甲基化.
- 通过增加RB1增强剂的H3K27ac丰富度,对EZH2的药理抑制可提高RB1表达的调节.
结论:
- EZH2是TNBC中RB1的一个关键表观遗传调节器.
- 用药理学剂向EZH2可以恢复TNBC中的RB1表达.
- 通过EZH2抑制恢复RB1功能,为TNBC中RB1介导的耐药性提供了潜在的治疗策略.
更多相关视频
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
相关概念视频
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Negative Regulator Molecules
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...